EFFICACY AND SAFETY OF INTRAVENOUS KETAMINE TREATMENT IN JAPANESE PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Background

Whereas ketamine's antidepressant effect for treatment-resistant depression (TRD) has been consistent in the literature from the North American and European countries (1-3), its evidence is scarce among the Asian population (4-6).

Aims & Objectives

We aimed to evaluate the efficacy and safety of intravenous ketamine treatment in Japanese patients with TRD.

Method

In this double-blind randomized placebo-controlled trial, 34 Japanese patients (41.4±9.4 years, 23 men [67.6%]) with TRD were randomized to receive either intravenous ketamine (0.5 mg/kg) or placebo, administered over 40 minutes, twice a week, for two weeks. The primary outcome measure was the change from baseline to post-treatment in the Montgomery-Å sberg Depression Rating Scale (MADRS) total score. Moreover, changes and percent changes in depressive symptomatology scores measured with 17-item Hamilton Depression Rating Scale (HDRS-17), Quick Inventory of Depressive Symptoms Self-Rated (QIDS-SR), 6-item Hamilton Depression Rating Scale (HDRS-6), and rates of remission (i.e., a 10 or less on the MADRS total score), response (i.e., a 50% or more reduction from baseline in the MADRS total score), and partial response (i.e., a 25% or more reduction from baseline in the MADRS total score) were compared between the groups. The values of interest were analyzed on an intention-to-treat (ITT) or per-protocol (PP) basis. Baseline values were used as endpoint values for dropouts in ITT analysis whereas only completers were analyzed in PP analysis. Multiple and logistic regression analyses were conducted to explore the demographic and clinical characteristics associated with the change in the MADRS total score and presence of remission, response, and partial response to ketamine, respectively.

Results

There was no significant reduction in the MADRS total score between the ketamine (n=17) and placebo (n=17) groups on ITT analysis (-8.1 ± 10.0 vs -2.5 ± 5.2, p=0.052); however, there was a significant reduction in the ketamine group (n=15) compared to the placebo group (n=16) on PP analysis (-9.1 ± 10.2 vs -2.7 ± 5.3, p=0.034). Moreover, the ketamine group showed superiority in the percent change in the MADRS score on PP analysis and the HDRS-17 and HDRS-6 scores on ITT and PP analysis. No significant superiority was observed in other outcome measures in the ketamine group compared to the placebo group. Treatment-emergent adverse events were more frequent in the ketamine group than in the placebo group, whereas no serious adverse events were reported. Multiple regression analysis revealed that body mass index and MADRS total score at baseline were negatively associated with the change in the MADRS total score (beta=-0.42, p=0.045; beta=-0.31, p=0.039, respectively). Logistic regression analysis did not find any factor in association with presence of remission, response, nor partial response.

Discussion & Conclusion

The present study demonstrated that the intravenous ketamine treatment outperformed the placebo in alleviating depressive symptoms in Japanese patients with TRD who completed the study, especially in patients with high body mass index and severe symptomatology at baseline. This study suggests that the intravenous ketamine treatment may benefit Asian patients with TRD. Since ethnic differences could impact clinical response (7, 8), further investigations are warranted in populations with various ethnic backgrounds.

References

1.Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.

2.Zarate CA, Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.

3.Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB, et al. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015;172(10):950-66.

4.Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology. 2017;42(13):2482-92.

5.Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J Psychiatr Res. 2018;106:61-8.

6.Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. 2021;21(1):526.

7.Kanazawa A, White PM, Hampson SE. Ethnic variation in depressive symptoms in a community sample in Hawaii. Cultur Divers Ethnic Minor Psychol. 2007;13(1):35-44.

8.Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. J Clin Pharm Ther. 2000;25(3):197-220.